Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kanne

Diagnostic Radiology Madison, WI Medical Doctor

NPI 1639186463 CMS profile 381275

600 Highland Ave, Madison, WI 53792

Open in the dashboard

General payments

$226,850

59 records reported · program years 2019–2025

Research payments

$13,000

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kanne of Madison, WI is reported in the CMS Open Payments database as having received $226,850 across 59 general payments and $13,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,100 2
2024 General $87,250 9
2023 General $20,600 7
2022 General $10,500 9
2021 General $7,100 12
2021 Research $1,500 1
2020 General $6,600 9
2020 Research $2,600 1
2019 General $92,700 11
2019 Research $8,900 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kanne
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Jeffrey Kanne were reported at $2,100. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Jeffrey Kanne Diagnostic Radiology median Middle half National median
2019 $92,700 $108 $29–$318 $163
2020 $6,600 $65 $21–$252 $114
2021 $7,100 $92 $24–$292 $132
2022 $10,500 $104 $29–$294 $149
2023 $20,600 $110 $29–$337 $160
2024 $87,250 $113 $30–$356 $164
2025 $2,100 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $133,150 46 payments
  2. Merck Sharp & Dohme Corporation $92,700 11 payments
  3. Acerta Pharma LLC $1,000 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $226,850 59 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $125,450 37 payments
  2. NOXAFIL $92,700 11 payments
  3. FASENRA Respiratory $6,600 9 payments
  4. TAGRISSO $2,100 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Celgene Corporation $13,000 3 payments

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$205,054

Of which drugs: $582

Medicare patients

5,199

Average age 73

Services billed

14,295

2,658 women, 2,541 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Ischemic heart disease 34%
Chronic kidney disease 33%
Diabetes 32%
Heart failure 30%
Cancer 29%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 60 5,695 $581

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca UK Limited $87,250
$87,250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record